Profile data is unavailable for this security.
About the company
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
- Revenue in USD (TTM)0.00
- Net income in USD-20.39m
- Incorporated2017
- Employees2.00
- LocationNRX Pharmaceuticals Inc1201 ORANGE STREET, SUITE 600WILMINGTON 19801United StatesUSA
- Phone+1 (484) 254-6134
- Fax+1 (302) 575-1642
- Websitehttps://www.nrxpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKGen Biotech Inc | 0.00 | -88.25m | 11.27m | 63.00 | -- | -- | -- | -- | -3.74 | -3.74 | 0.00 | -2.71 | 0.00 | -- | -- | 0.00 | -480.25 | -- | -- | -- | -- | -- | -- | -- | -- | -0.4822 | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.47m | -97.61m | 11.65m | 87.00 | -- | 0.5651 | -- | 7.92 | -1.51 | -1.51 | 0.0229 | 0.315 | 0.0148 | -- | -- | 16,715.91 | -97.94 | -58.01 | -118.22 | -68.69 | -- | -- | -6,635.76 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Viaderma Inc | 17.80m | 2.31m | 11.72m | 75.00 | 0.0006 | 0.00004 | 2.17 | 0.6585 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Aspira Women's Health Inc | 8.92m | -15.95m | 11.73m | 64.00 | -- | -- | -- | 1.31 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 11.87m | 4.00 | -- | -- | -- | 15,824.20 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Sol Gel Technologies Ltd | 11.71m | -9.57m | 12.29m | 36.00 | -- | 0.354 | -- | 1.05 | -0.3435 | -0.3435 | 0.4202 | 1.25 | 0.2522 | -- | 3.34 | 325,194.40 | -20.62 | -31.60 | -23.40 | -35.49 | -- | -- | -81.75 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -29.80m | 12.53m | 28.00 | -- | 0.2736 | -- | -- | -1.19 | -1.19 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -44.18 | -47.03 | -48.36 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0222 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| AIM ImmunoTech Inc | 201.00k | -28.05m | 12.74m | 26.00 | -- | 1.87 | -- | 63.39 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| HST Global Inc | 0.00 | -123.45k | 12.80m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.08m | 12.92m | 3.00 | -- | 3.79 | -- | -- | -0.0179 | -0.0179 | 0.00 | 0.0198 | 0.00 | -- | -- | 0.00 | -38.42 | 27.48 | -38.90 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -20.39m | 13.01m | 2.00 | -- | -- | -- | -- | -1.69 | -1.69 | 0.00 | -1.65 | 0.00 | -- | -- | -- | -231.96 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -104.47 | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | 4.50m | 13.21m | 2.00 | 3.40 | 0.2782 | 2.94 | -- | 0.5058 | 0.5058 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | 35.90 | -7.42 | 38.19 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -140.79m | 13.58m | 16.00 | -- | -- | -- | 60.11 | -141.34 | -141.34 | 0.2473 | -0.6719 | 0.0126 | -- | 0.2113 | 14,125.00 | -782.70 | -63.43 | -1,568.46 | -85.72 | -- | -- | -62,294.25 | -3,257.92 | -- | -- | -- | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Cingulate Inc | 0.00 | -16.35m | 14.39m | 13.00 | -- | 1.13 | -- | -- | -70.83 | -70.83 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -168.10 | -- | -268.55 | -- | -- | -- | -- | -- | -- | -141.37 | 0.0007 | -- | -- | -- | -33.14 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -3.31m | 14.83m | 9.00 | -- | -- | -- | -- | -0.4357 | -0.4357 | 0.00 | -3.10 | 0.00 | -- | -- | 0.00 | -6.25 | -49.89 | -6.75 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to NRX Pharmaceuticals Inc's reporting currency: US Dollar USD
6.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 240.32k | 2.24% |
| Anson Funds Management LPas of 30 Sep 2024 | 142.53k | 1.33% |
| AdvisorShares Investments LLCas of 30 Sep 2024 | 130.09k | 1.21% |
| Geode Capital Management LLCas of 30 Sep 2024 | 77.34k | 0.72% |
| Sabby Management LLCas of 30 Sep 2024 | 35.05k | 0.33% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 29.08k | 0.27% |
| Virtu Americas LLCas of 30 Jun 2024 | 17.04k | 0.16% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 16.72k | 0.16% |
| Townsquare Capital LLCas of 30 Sep 2024 | 15.04k | 0.14% |
| One Wealth Management Investment & Advisory Services LLCas of 30 Sep 2024 | 15.04k | 0.14% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
